Clinical Trials Logo

Hemoglobinuria, Paroxysmal clinical trials

View clinical trials related to Hemoglobinuria, Paroxysmal.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT06449001 Not yet recruiting - Clinical trials for Paroxysmal Nocturnal Hemoglobinuria

Study of Danicopan as Add-on Treatment to Ravulizumab or Eculizumab in Pediatric Participants With PNH Who Have Clinically Significant Extravascular Hemolysis

Start date: August 23, 2024
Phase: Phase 3
Study type: Interventional

The primary objective of this study is to evaluate efficacy of danicopan as add-on treatment to ravulizumab or eculizumab as assessed by hemoglobin (Hgb) change from Baseline at Week 12 in pediatric participants with paroxysmal nocturnal hemoglobinuria (PNH) and clinically significant extravascular hemolysis (CS-EVH).

NCT ID: NCT06411626 Not yet recruiting - Clinical trials for Paroxysmal Nocturnal Hemoglobinuria

Home Reported Outcomes in PNH

Start date: June 15, 2024
Phase:
Study type: Observational

The study aims to longitudinally capture the full spectrum of symptoms, treatment utilization, and overall Health-Related Quality of Life (HRQoL) experienced by PNH patients. By primarily utilizing home reported outcomes (HRO) data on symptom burden and treatment usage, supplemented with patient-reported outcome (PRO) measures, the study seeks to establish a new real-world data (RWD) source to understand symptom variability and HRQoL among PNH patients, including those receiving orally administered iptacopan.

NCT ID: NCT06312644 Not yet recruiting - Pregnancy Clinical Trials

Study of Ultomiris® (Ravulizumab) Safety in Pregnancy

Start date: March 29, 2024
Phase:
Study type: Observational [Patient Registry]

The primary objective of this study is to describe the frequency and characteristics of pregnancy outcomes and maternal complications among participants exposed to Ultomiris and to describe the frequency and characteristics of selected fetal/neonatal/infant outcomes in utero, at birth, and through 1 year of age after exposure in utero or via breastmilk.

NCT ID: NCT06134414 Not yet recruiting - Clinical trials for Paroxysmal Nocturnal Hemoglobinuria (PNH)

Study of Safety and Efficacy of MY008211A in in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)

Start date: December 2024
Phase: Phase 2
Study type: Interventional

The main purpose of this study is to evaluate the efficacy of MY008211A in adult patients with PNH, showing signs of active hemolysis.

NCT ID: NCT05731050 Not yet recruiting - Clinical trials for PNH - Paroxysmal Nocturnal Hemoglobinuria

Study of NM8074 in Soliris-Treated Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)

Start date: June 2025
Phase: Phase 2
Study type: Interventional

The proposed study, NM8074-PNH-101, is a phase II, open-label, multi-dose, unicenter trial to evaluate the safety and efficacy of NM8074 in Soliris-treated PNH subjects.

NCT ID: NCT05646563 Not yet recruiting - Clinical trials for Paroxysmal Nocturnal Hemoglobinuria

Study of NM8074 in Adult PNH Patients With Inadequate Response to Soliris

Start date: March 2025
Phase: Phase 2
Study type: Interventional

This is a Phase II, open-label study designed to evaluate the safety, efficacy, and immunogenicity of NM8074 in PNH patients undergoing complement-inhibitor therapy with Soliris.

NCT ID: NCT05646524 Not yet recruiting - Clinical trials for Paroxysmal Nocturnal Hemoglobinuria

Study of Efficacy and Safety of NM8074 in Adult PNH Patients Who Are Naive to Complement Inhibitor Therapy

Start date: January 2025
Phase: Phase 2
Study type: Interventional

This is a Phase II, open-label study designed to evaluate the safety, efficacy, and immunogenicity of NM8074 administered intravenously to adult patients with Paroxysmal Nocturnal Hemoglobinuria (PNH).

NCT ID: NCT03866681 Not yet recruiting - Clinical trials for Paroxysmal Nocturnal Hemoglobinuria

Sirolimus Combined With Low-dose Warfarin for the Treatment of Refractory PNH

Start date: April 1, 2019
Phase: Phase 4
Study type: Interventional

Classical paroxysmal nocturnal hemoglobinuria(PNH) is mainly characterized by hemolysis and thrombosis, which reduced patients ' quality of life(QoL) greatly and even lead to death. Glucocorticoids and symptomatic supportive therapy are traditional treatments and the response rate is far from satisfactory. Eculizumab is an effective therapy but it is expensive and not available in China mainland.The investigators aim to explore the efficacy and safety of sirolimus for refractory classic PNH.